The global cancer vaccines market is expanding steadily as rising cancer prevalence, advances in immunotherapy, and increasing adoption of preventive healthcare reshape the oncology landscape. The market was valued at US$9.70 billion in 2023 and stood at US$9.84 billion in 2024. It is projected to reach US$15.00 billion by 2032, registering a CAGR of 5.4% from 2024 to 2032.
The growing adoption of HPV vaccines for cervical cancer prevention, emergence of neoantigen-based and mRNA vaccines, and continued advances in cancer immunotherapy are expected to support market expansion. Increasing investments in R&D and strategic partnerships, including collaborations in oncology, are accelerating innovation in the cancer vaccine field.
A robust product pipeline, including mRNA-4157, Tedopi, GLSI-100, and other emerging cancer vaccine candidates, is expected to contribute to market development in the coming years. Growing efforts to develop personalized and therapeutic cancer vaccines are also creating new opportunities across developed and emerging markets.
Cancer Vaccines Market Size by Region and Country
The regional outlook indicates continued growth across North America, Europe, Asia Pacific, and Latin America. North America represents a significant market supported by increasing cancer incidence, healthcare expenditure, and adoption of personalized immunotherapy approaches. Asia Pacific is also witnessing sustained expansion, driven by rising cancer prevalence, healthcare infrastructure development, and government initiatives promoting preventive oncology.
North America Cancer Vaccines Market
The North America cancer vaccines market was valued at US$2,405.5 million in 2024 and is projected to reach US$4,224.8 million by 2029, representing a CAGR of 7.3%.
North America’s cancer vaccines market is poised for sustained expansion through 2029, supported by rising cancer incidence, growing healthcare expenditure, and increasing adoption of advanced immunotherapy and preventive oncology approaches.
US Cancer Vaccines Market
The US cancer vaccines market was valued at US$2,129.3 million in 2024 and is projected to reach US$2,950.4 million by 2029, representing a CAGR of 4.2%.
The US cancer vaccines market is positioned for sustained growth through 2029, driven by increasing cancer incidence, rising healthcare expenditure, and growing adoption of personalized immunotherapy approaches. Continued development of therapeutic and preventive cancer vaccines is expected to create opportunities for market expansion.
Canada Cancer Vaccines Market
The Canada cancer vaccines market was valued at US$181.1 million in 2024 and is projected to reach US$196.4 million by 2029, representing a CAGR of 1.0%.
Canada’s cancer vaccines market is positioned for steady, albeit modest, expansion through 2029, driven by increasing clinical adoption and the integration of cancer vaccine approaches into provincial healthcare systems.
Europe Cancer Vaccines Market
The Europe cancer vaccines market was valued at US$1,522.9 million in 2024 and is projected to reach US$2,343.1 million by 2029, representing a CAGR of 5.5%.
Europe’s cancer vaccines market is positioned for sustained growth through 2029, driven by increasing investment in oncology research, expanding clinical trial pipelines, and growing healthcare provider adoption of preventive immunotherapy approaches.
| Market | 2024 Value | 2029 Value | CAGR |
|---|---|---|---|
| Europe | US$1,522.9 Million | US$2,343.1 Million | 5.5% |
| Germany | US$417.5 Million | US$590.1 Million | 4.4% |
| UK | US$285.2 Million | US$398.1 Million | 4.3% |
| France | US$226.1 Million | US$313.1 Million | 4.2% |
| Italy | US$192.3 Million | US$264.5 Million | 4.1% |
| Spain | US$139.7 Million | US$189.6 Million | 3.9% |
| Rest of Europe | US$201.9 Million | US$276.8 Million | 4.0% |
Germany Cancer Vaccines Market
The Germany cancer vaccines market was valued at US$417.5 million in 2024 and is projected to reach US$590.1 million by 2029, representing a CAGR of 4.4%.
Germany’s cancer vaccines market is poised for steady expansion through 2029, supported by increasing cancer prevalence and growing investment in immunotherapy research.
UK Cancer Vaccines Market
The UK cancer vaccines market was valued at US$285.2 million in 2024 and is projected to reach US$398.1 million by 2029, representing a CAGR of 4.3%.
The UK cancer vaccines market is positioned for sustained growth through 2029, driven by increasing NHS adoption of immunotherapies and growing patient awareness of preventive oncology solutions.
France Cancer Vaccines Market
The France cancer vaccines market was valued at US$226.1 million in 2024 and is projected to reach US$313.1 million by 2029, representing a CAGR of 4.2%.
France’s cancer vaccines market is positioned for steady expansion, supported by increasing healthcare investments in preventive oncology and immunotherapy innovations.
Italy Cancer Vaccines Market
The Italy cancer vaccines market was valued at US$192.3 million in 2024 and is projected to reach US$264.5 million by 2029, representing a CAGR of 4.1%.
Italy’s cancer vaccines market is positioned for steady growth through 2029, supported by an aging population with rising cancer incidence rates and increasing healthcare expenditure on advanced oncology treatments.
Spain Cancer Vaccines Market
The Spain cancer vaccines market was valued at US$139.7 million in 2024 and is projected to reach US$189.6 million by 2029, representing a CAGR of 3.9%.
Spain’s cancer vaccines market is poised for steady growth through 2029, driven by rising cancer incidence rates and the country’s commitment to advancing oncology therapeutics.
Rest of Europe Cancer Vaccines Market
The Rest of Europe cancer vaccines market was valued at US$201.9 million in 2024 and is projected to reach US$276.8 million by 2029, representing a CAGR of 4.0%.
Rest of Europe’s cancer vaccines market is positioned for sustained growth, driven by increasing healthcare investments and rising awareness of preventive oncology.
Asia Pacific Cancer Vaccines Market
The Asia Pacific cancer vaccines market was valued at US$4,222.8 million in 2024 and is projected to reach US$6,150.4 million by 2029, representing a CAGR of 4.8%.
The Asia Pacific cancer vaccines market is poised for sustained growth through 2029, supported by rising cancer incidence rates, expanding healthcare infrastructure, and increasing government initiatives promoting preventive oncology therapies.
| Market | 2024 Value | 2029 Value | CAGR |
|---|---|---|---|
| Asia Pacific | US$4,222.8 Million | US$6,150.4 Million | 4.8% |
| China | US$2,237.1 Million | US$3,359.4 Million | 5.2% |
| Japan | US$393.0 Million | US$620.2 Million | 5.9% |
| India | US$706.7 Million | US$1,013.4 Million | 4.6% |
| South Korea | US$257.8 Million | US$351.9 Million | 4.0% |
| Rest of Asia Pacific | US$593.0 Million | US$763.4 Million | 3.2% |
China Cancer Vaccines Market
The China cancer vaccines market was valued at US$2,237.1 million in 2024 and is projected to reach US$3,359.4 million by 2029, representing a CAGR of 5.2%.
China’s cancer vaccines market is poised for sustained expansion through 2029, driven by rising cancer incidence, government healthcare initiatives, and increased R&D investments in immunotherapy.
Japan Cancer Vaccines Market
The Japan cancer vaccines market was valued at US$393 million in 2024 and is projected to reach US$620.2 million by 2029, representing a CAGR of 5.9%.
Japan’s cancer vaccines market is poised for steady expansion, supported by its aging population, advanced healthcare infrastructure, and strong pharmaceutical R&D capabilities.
India Cancer Vaccines Market
The India cancer vaccines market was valued at US$706.7 million in 2024 and is projected to reach US$1,013.4 million by 2029, representing a CAGR of 4.6%.
India’s cancer vaccines market is poised for steady expansion through 2029, driven by escalating cancer prevalence, heightened healthcare awareness, and supportive government policies emphasizing preventive medicine.
South Korea Cancer Vaccines Market
The South Korea cancer vaccines market was valued at US$257.8 million in 2024 and is projected to reach US$351.9 million by 2029, representing a CAGR of 4.0%.
South Korea’s cancer vaccines market is positioned for sustained expansion through 2029, supported by an aging population with rising cancer prevalence and government-backed healthcare initiatives.
Rest of Asia Pacific Cancer Vaccines Market
The Rest of Asia Pacific cancer vaccines market was valued at US$593 million in 2024 and is projected to reach US$763.4 million by 2029, representing a CAGR of 3.2%.
Rest of Asia Pacific’s cancer vaccines market is positioned for steady growth as healthcare systems modernize and cancer prevention gains priority across emerging markets.
Latin America Cancer Vaccines Market
The Latin America cancer vaccines market was valued at US$700.3 million in 2024 and is projected to reach US$983.3 million by 2029, representing a CAGR of 4.3%.
Latin America’s cancer vaccines market is positioned for sustained growth through 2029, driven by escalating cancer incidence rates and enhanced healthcare spending across the region.
| Market | 2024 Value | 2029 Value | CAGR |
|---|---|---|---|
| Latin America | US$700.3 Million | US$983.3 Million | 4.3% |
| Brazil | US$335.9 Million | US$466.1 Million | 4.2% |
| Mexico | US$107.4 Million | US$141.8 Million | 3.5% |
| Rest of Latin America | US$245.6 Million | US$317.1 Million | 3.2% |
Brazil Cancer Vaccines Market
The Brazil cancer vaccines market was valued at US$335.9 million in 2024 and is projected to reach US$466.1 million by 2029, representing a CAGR of 4.2%.
Brazil’s cancer vaccines market demonstrates resilient growth momentum, supported by escalating cancer incidence rates and strengthened healthcare infrastructure investments.
Mexico Cancer Vaccines Market
The Mexico cancer vaccines market was valued at US$107.4 million in 2024 and is projected to reach US$141.8 million by 2029, representing a CAGR of 3.5%.
Mexico’s cancer vaccines market is positioned for steady expansion as healthcare infrastructure continues to modernize and oncology treatment accessibility improves across the country.
Rest of Latin America Cancer Vaccines Market
The Rest of Latin America cancer vaccines market was valued at US$245.6 million in 2024 and is projected to reach US$317.1 million by 2029, representing a CAGR of 3.2%.
Rest of Latin America’s cancer vaccines market demonstrates steady growth potential, driven by expanding healthcare infrastructure and increasing adoption of preventive medicine.
Cancer Vaccines Market Outlook
The global cancer vaccines market is entering a period of continued development, supported by rising cancer prevalence, advances in immunotherapy, and growing emphasis on cancer prevention. The market was valued at US$9.84 billion in 2024 and is projected to reach US$15.00 billion by 2032, reflecting a CAGR of 5.4% during 2024–2032.
North America and Europe continue to benefit from established healthcare systems, pharmaceutical R&D capabilities, and increasing adoption of advanced oncology treatments. Meanwhile, Asia Pacific represents an important regional market supported by high cancer prevalence, expanding healthcare infrastructure, and government initiatives focused on preventive healthcare.
The continued development of HPV vaccines, neoantigen-based vaccines, mRNA-based approaches, and other therapeutic cancer vaccines is expected to remain central to market development. A growing clinical pipeline and increasing investments in personalized cancer immunotherapy are also expected to support innovation across the global cancer vaccines market.
